Navigation Links
Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
Date:9/24/2013

LONDON, Sept. 24, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the Company has begun a two-week clinical trial designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

The trial, which began on September 23rd, 2013, is being conducted in partnership with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH").

Naloxone is a medicine currently available through injection that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake is working on a new intranasal delivery system for the delivery of naloxone that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S. According to the Centers for Disease Control and Prevention, 16,651 people died from prescription opioid overdose in the U.S. in 2010, a significant increase from the 4,030 overdose deaths in 1999.

Assuming favorable outcomes from this study, NIDA plans to file an IND for a larger study. The expected goal of Lightlake's partnership with NIDA is to have an FDA approved intranasal naloxone solution for the reversal of opioid overdoses that can be brought to market within 12 to 18 months.

"We are very pleased to begin our trial with NIDA as we believe this is a key step that will help us to formally deliver an intranasal naloxone spray aimed at reversing opioid overdoses to the healthcare community," stated Dr. Roger Crystal, CEO of Lightlake. "Naloxone is the ideal opioid antagonist and we are confident that the data from this trial can also be used to supply critical data for other Lightlake studies that involve va
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
2. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
3. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
4. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
5. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
6. Adheron Therapeutics Names New Senior Leadership
7. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
8. Echo Therapeutics Sends Response to Shareholder Letter
9. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
10. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
11. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... April 16, 2015  Schulman Associates IRB, Inc., the ... signed a long-term lease on Laboratory Drive in the ... . The location will house review board and ... high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates Management, ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World ... with hemophilia advocacy groups to illuminate more than 15 prominent ... including Boston,s Zakim Bridge and Prudential ... New Orleans, Mercedes-Benz Superdome and Denver,s ... during the evening of April 17, and coincide with hemophilia ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4
... with its goal of extending electronic government and ... how such a massive undertaking can take place ... sharing information and integrating systems has been clear ... , ,What has been missing is the organizational ...
... carefully established position as a nexus for research and development ... academic and other research institutions, according to a new report. ... This prediction comes from the Wisconsin Technology Council ... report, titled The Economic Value of Academic Research and Development ...
... Institutes of Health. Madison, Wis. ... Wednesday that it will receive a $1.26 million Phase II ... Health. , ,The funds will be used to help produce ... disorder that kills red blood cells. This results in a ...
Cached Biology Technology:State CIO wants to unify electronic government 2State CIO wants to unify electronic government 3State CIO wants to unify electronic government 4Economic report raises red flags on Wisconsin's future 2Economic report raises red flags on Wisconsin's future 3Mirus receives $1.26 million SBIR grant to combat anemia 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... assumed that if mercury is high and increasing in fish ... true of fish elsewhere in the Arctic. But a ... discovered that assumption is wrong in much of the continental ... a result of diverse atmospheric, geological, and biological conditions, "It ...
... developed a new vaccine that protects against lethal pneumonia ... drug-resistant strains like MRSA. The research team was ... in the UI Carver College of Medicine. The findings ... Infectious Disease . The new vaccine targets toxins ...
... , a sprawling shrub that grows on just a single ... in its family and genus. It is also one of ... 200 million years ago. Now, researchers from Indiana University, with ... Penn State University, and the Institute of Research for Development ...
Cached Biology News:Virginia Tech research overturns assumption about mercury in the Arctic 2Virginia Tech research overturns assumption about mercury in the Arctic 3Staph stoppers 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
...
... The Luminex 200 IS System is ideal ... Upstate's Beadlyte reagents. This system contains the ... developed by Luminex. The user can design ... kits. The system has fully integrated graphing ...
... Quality ISO 9001:2000 Certified USDA Research ... Validated, SOP's Training AALAS Certified ... All Procedures GLP Documentation Upon Request ... shopping point for all your custom immunology ...
... Re-Blot Western Blot Recycling Kit is ... Western blots that have been developed ... other isotopes. It is not recommended ... 4-chloronapthol, etc.), as it is not ...
Biology Products: